The short answer
Weight lost on incretin therapy is not all fat. In the Phase 2 BELIEVE trial, adults on semaglutide alone lost 7.4% of lean mass; adding bimagrumab reduced that to 2.9% while producing greater total reduction of 22.1%, of which 92.8% was fat mass.
Key facts
- Lean loss, semaglutide alone
- 7.4%
- Lean loss, plus bimagrumab
- 2.9%
- Total reduction, combination
- 22.1%
- Fat share of that loss
- 92.8%
- Lean fraction of total loss
- ~21% → ~7%
- Bimagrumab target
- Activin type II receptor
- Trial
- BELIEVE, Phase 2, published in Nature Medicine
Why the composition of weight loss matters
A scale reports mass, not what the mass was. Skeletal muscle contributes to metabolic rate, glucose disposal, physical function and, in older populations, to the ability to remain independent. Losing a substantial fraction of it alongside fat is a materially different outcome from losing fat alone, even when the headline percentage is identical.
How much lean mass is involved
Reported estimates run as high as 40% of total weight lost coming from lean tissue, though figures vary with population, measurement method and duration. In the BELIEVE trial specifically, semaglutide alone produced 7.4% lean mass loss, corresponding to roughly 21% of total weight lost. Different studies produce different numbers, and body-composition measurement methods are not interchangeable.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What bimagrumab is
Bimagrumab is a monoclonal antibody against the activin type II receptor. Blocking that receptor interrupts myostatin and activin signalling, the pathway that restrains skeletal muscle growth. Inhibiting a brake on muscle mass is a mechanistically different intervention from anything the incretins do, which is why it combines with them rather than competing.
The BELIEVE result
Adding bimagrumab to semaglutide reduced lean mass loss from 7.4% to 2.9%, while total reduction reached 22.1% with 92.8% of it fat mass. Expressed as a fraction, the lean share of total loss fell from roughly 21% to about 7%. The combination therefore produced more total reduction and a substantially better composition, which is an unusual pairing of outcomes.
How to read this cautiously
BELIEVE is Phase 2. Body composition is a surrogate: better composition is assumed to translate into better function and outcomes, and that assumption is reasonable but not demonstrated by this trial. A 2026 systematic review and meta-analysis in Diabetes, Obesity and Metabolism examined bimagrumab in obesity and metabolic dysfunction more broadly, and the activin/myostatin pathway as a muscle-preservation target has its own 2026 review literature.
Why this became a prominent question in 2026
As incretins moved toward 20% and beyond, the absolute quantity of tissue lost grew with them. At 5% reduction the composition question is academic; at 25% it is not. The compounds getting more effective is what made this a live issue rather than a footnote.
Quick reference
| Semaglutide alone | Semaglutide + bimagrumab | |
|---|---|---|
| Lean mass lost | 7.4% | 2.9% |
| Total weight reduction | Lower | 22.1% |
| Fat share of loss | ~79% | 92.8% |
| Lean share of loss | ~21% | ~7% |
Frequently asked questions
Do all GLP-1 drugs cause lean mass loss?
Weight loss from any cause includes some lean tissue. The question is the proportion, which varies by compound, population, duration and measurement method.
How does bimagrumab work?
It is an antibody against the activin type II receptor, blocking myostatin and activin signalling, the pathway that limits skeletal muscle mass.
Is bimagrumab approved?
No. BELIEVE is a Phase 2 trial and the compound holds no marketing authorisation.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBimagrumab in adults with obesity. systematic review, Diabetes Obes Metab 2026 (PMID 42530342)pubmed.ncbi.nlm.nih.gov
- PubMedTargeting the activin/myostatin-ActRII pathway. Rev Endocr Metab Disord 2026 (PMID 41954678)pubmed.ncbi.nlm.nih.gov
- RefCombination GLP-1 therapy preserves lean mass. EurekAlerteurekalert.org
- RefNew GLP-1 therapies and muscle preservation. American Diabetes Associationdiabetes.org
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Cagrilintide? The Amylin Half of CagriSemaCagrilintide is a long-acting amylin analogue engineered for weekly dosing. Why native amylin could never be a drug, and what the analogue changed.
- What Is Exenatide? From Gila Monster Venom to MedicineExenatide is a synthetic version of exendin-4, found in Gila monster venom. Why a lizard peptide resists DPP-4 when human GLP-1 does not.
- What Is Liraglutide? The Bridge GenerationLiraglutide uses a C16 fatty acid for albumin binding, giving daily dosing. The step between exenatide and semaglutide, and what changed between them.
- Why Nausea and Efficacy Come From the Same MechanismGLP-1 slows gastric emptying and signals through the area postrema - the brainstem region governing both satiety and nausea. Why the two cannot be separated.
- Biased Agonism at the GLP-1 ReceptorTwo agonists at the same receptor can produce different outcomes by favouring cAMP over β-arrestin. Why tirzepatide internalises the receptor less than GLP-1.